|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Greten TF, Wang XW and Korangy F: Current
concepts of immune based treatments for patients with HCC: From
basic science to novel treatment approaches. Gut. 64:842–848. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kapanidou M, Curtis NL and Bolanos-Garcia
VM: Cdc20: At the Crossroads between chromosome segregation and
mitotic exit. Trends Biochem Sci. 42:193–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schrock MS, Stromberg BR, Scarberry L and
Summers MK: APC/C ubiquitin ligase: Functions and mechanisms in
tumorigenesis. Semin Cancer Biol. 67:80–91. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong S, Huang F, Zhang H and Chen Q:
Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues
predicts poor survival in pancreatic ductal adenocarcinoma. Biosci
Rep. Feb 26–2019.doi: 10.1042/BSR20182306. View Article : Google Scholar
|
|
9
|
Parmar MB, K C RB, Löbenberg R and Uludağ
H: Additive polyplexes to undertake siRNA therapy against CDC20 and
Survivin in breast cancer cells. Biomacromolecules. 19:4193–4206.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De K, Grubb TM, Zalenski AA, Pfaff KE, Pal
D, Majumder S, Summers MK and Venere M: Hyperphosphorylation of
CDH1 in glioblastoma cancer stem cells attenuates APC/C
CDH1 activity and pharmacologic inhibition of APC/C
CDH1/CDC20 compromises viability. Mol Cancer Res.
17:1519–1530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim Y, Choi JW, Lee JH and Kim YS: Spindle
assembly checkpoint MAD2 and CDC20 overexpressions and cell-in-cell
formation in gastric cancer and its precursor lesions. Hum Pathol.
85:174–183. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J,
Lu M, Peng S, Qiu J and Gao X: Silencing of CDC20 suppresses
metastatic castration-resistant prostate cancer growth and enhances
chemosensitivity to docetaxel. Int J Oncol. 49:1679–1685. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Q, Huang H, Liu A, Li J, Liu C, Sun
B, Chen L, Gao Y, Xu D and Su C: Cell division cycle 20 (CDC20)
drives prostate cancer progression via stabilization of β-catenin
in cancer stem-like cells. EBioMedicine. 42:397–440. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Diepenbruck M and Christofori G:
Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no,
maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu H, Zhang W, Wu ZR, Liu Y, Shi Y, Gong
J, Shen W and Liu C: MiR-29c-3p regulates DNMT3B and LATS1
methylation to inhibit tumor progression in hepatocellular
carcinoma. Cell Death Dis. 10:482019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Z, He M, Shah AA and Wan Y: Insights
into APC/C: From cellular function to diseases and therapeutics.
Cell Div. 11:92016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McLean JR, Chaix D, Ohi MD and Gould KL:
State of the APC/C: Organization, function, and structure. Crit Rev
Biochem Mol Biol. 46:118–136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng S, Castillo V and Sliva D: CDC20
associated with cancer metastasis and novel mushroom-derived CDC20
inhibitors with antimetastatic activity. Int J Oncol. 54:2250–2256.
2019.PubMed/NCBI
|
|
23
|
Alfarsi LH, Ansari RE, Craze ML, Toss MS,
Masisi B, Ellis IO, Rakha EA and Green AR: CDC20 expression in
oestrogen receptor positive breast cancer predicts poor prognosis
and lack of response to endocrine therapy. Breast Cancer Res Treat.
178:535–544. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang J, Zhou F, Li Y, Li Q, Wu Z, Yu L,
Yuan F, Liu J, Tian Y, Cao Y, et al: Cdc20 overexpression is
involved in temozolomide-resistant glioma cells with
epithelial-mesenchymal transition. Cell Cycle. 16:2355–2365. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chu Z, Zhang X, Li Q, Hu G, Lian CG and
Geng S: CDC20 contributes to the development of human cutaneous
squamous cell carcinoma through the Wnt/β-catenin signaling
pathway. Int J Oncol. 54:1534–1544. 2019.PubMed/NCBI
|
|
26
|
Sun C, Li M, Feng Y, Sun F, Zhang L, Xu Y,
Lu S, Zhu J, Huang J, Wang J, et al: MDM2-P53 signaling
pathway-mediated upregulation of CDC20 promotes progression of
human diffuse large B-cell lymphoma. Onco Targets Ther.
13:10475–10487. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Couri T and Pillai A: Goals and targets
for personalized therapy for HCC. Hepatol Int. 13:125–137. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu M, Xue H, Wang Y, Shen Q, Jiang Q,
Zhang X, Li K, Jia M, Jia J, Xu J and Tian Y: MiR-345 inhibits
tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT
pathway in hepatocellular carcinoma. Int J Oncol. 50:975–983. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qiu E, Gao Y, Zhang B, Xia T, Zhang Z and
Shang G: Upregulation of cell division cycle 20 in cisplatin
resistance-induced epithelial-mesenchymal transition in
osteosarcoma cells. Am J Transl Res. 12:1309–1318. 2020.PubMed/NCBI
|
|
34
|
Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, Mo
Q, Liao L and Xu J: Twist1 promotes breast cancer invasion and
metastasis by silencing Foxa1 expression. Oncogene. 36:1157–1166.
2017. View Article : Google Scholar : PubMed/NCBI
|
